CAM
NKTR icon

Cormorant Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Cormorant Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,333
Closed -$400K – 117
2021
Q1 		$400K Sell
1,333
-1,334
-50% -$415K 0.01% 119
2020
Q4 		$680K Sell
2,667
-666
-20% -$172K 0.02% 103
2020
Q3 		$830K Sell
3,333
-5,000
-60% -$1.57M 0.03% 90
2020
Q2 		$2.9M Sell
8,333
-1,667
-17% -$520K 0.11% 74
2020
Q1 		$2.68M Sell
10,000
-3,333
-25% -$1.03M 0.12% 66
2019
Q4 		$4.32M Sell
13,333
-39,254
-75% -$11.4M 0.17% 63
2019
Q3 		$14.4M Buy
52,587
+25,920
+97% +$9.51M 0.87% 37
2019
Q2 		$14.2M Sell
26,667
-6,666
-20% -$3.34M 0.82% 39
2019
Q1 		$16.8M Sell
33,333
-3,134
-9% -$1.86M 1.14% 30
2018
Q4 		$18M Sell
36,467
-54,866
-60% -$33.1M 1.46% 25
2018
Q3 		$83.5M Sell
91,333
-8,667
-9% -$7.4M 5.43% 3
2018
Q2 		$73.2M Sell
100,000
-70,880
-41% -$81.7M 5.42% 5
2018
Q1 		$272M Buy
170,880
+37,700
+28% +$48.6M 20.3% 1
2017
Q4 		$119M Buy
+133,180
New +$78.8M 12.49% 2
2016
Q3 		– Sell
-134,859
Closed -$28.8M – 88
2016
Q2 		$28.8M Buy
134,859
+1,526
+1% +$341K 4.08% 5
2016
Q1 		$27.5M Buy
133,333
+82,323
+161% +$15.8M 4.14% 5
2015
Q4 		$12.9M Buy
51,010
+24,510
+92% +$5.04M 1.54% 24
2015
Q3 		$4.36M Hold
26,500
– – 0.7% 41
2015
Q2 		$4.97M Hold
26,500
– – 0.66% 42
2015
Q1 		$4.37M Sell
26,500
-3,500
-12% -$719K 0.68% 43
2014
Q4 		$6.97M Hold
30,000
– – 1.08% 28
2014
Q3 		$5.43M Buy
+30,000
New +$5.74M 1.12% 26

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Cormorant Asset Management's NKTR Position: Q2 2021 in Review

Cormorant Asset Management sold out of Nektar Therapeutics (NKTR) in Q2 2021, closing a stake of 1,333 shares — an estimated $400K sold.

Cormorant Asset Management first reported a position in NKTR in Q3 2014 and held it in 22 quarters. The position peaked at $272M in Q1 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2021.

  • Cormorant Asset Management reported no remaining Nektar Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 1,333 Nektar Therapeutics shares in Q2 2021, an estimated $400K.
  • Cormorant Asset Management first reported a position in Nektar Therapeutics in Q3 2014 and held it in 22 quarters.
  • Cormorant Asset Management's Nektar Therapeutics position peaked at $272M in Q1 2018.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2021.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.